Conditionally Active Antibodies for
Immuno-oncology
Corporate Deck | April 2024
Disclaimer
This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only.
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any
sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occ urring after the date hereof.
This presentation contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This presentation also contains "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, expectations regarding the development and potential therapeutic benefits of our
product candidates; the expected safety, pharmacokinetic and efficacy profile of our product candidates, including SNS-101; the expected timing of clinical data from our Phase 1/2 clinical trial of SNS-101; the expansion of the Phase 1 clinical trial to include additional patients with
specific tumor types; and our belief that our existing cash and cash equivalents will be sufficient to fund our operations at least into the fourth quarter of 2025 and reach midway into Phase 2 clinical studies of SNS-101.
When used in this presentation, the words and phrases "designed to," "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include
uncertainties inherent in the development of therapeutic product candidates, such as preclinical discovery and development; c onduct of clinical trials and related regulatory requirements, including the risk of delay or cessation of any clinical trials of Sensei's product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials and early results from the clinical trial of
SNS-101, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei's product candidates, including
SNS-101; our reliance on third parties over which we may not always have full control; risks regarding the accuracy of our estimates of
expenses, capital requirements and needs for additional financing; and other risk and uncertainties that are described in our Annual Report on Form 10-K filed with the SEC on or about February 29, 2024 and our other Periodic Reports filed with the SEC. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation and include all matters that are not historical facts.
Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in t he forward-looking
statements, even if new information becomes available in the future.
Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-
party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness , accuracy or
completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions andlimitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. F inally, while we believe our own internal research is reliable, such research has not been verified by any independent source.
Company Highlights
Sensei Bio's proprietary platform is designed to harness the unique acidic tumor microenvironment to widen the therapeutic window and enable druggability of promising oncology targets
SNS-101, the company's lead asset, targets VISTA, a critical negative regulator of T-cell function and promising immune checkpoint target
SNS-101 is currently in Phase 1 clinical testing with initial data displaying an attractive safety profile and potentially best-in-class pharmacokinetics
Anticipated near-term milestones include topline Phase 1 monotherapy & combination dose escalation data in Q2 2024
Three additional early-stage drug candidates
Cash runway into the fourth quarter of 2025, which is expected to fund operations midway into Phase 2 studies of SNS-101
Seasoned Leadership Team
John Celebi, MBA | Christopher Gerry, J.D. | Edward van der Horst, Ph.D. | Stephanie Krebs, M.S., MBA | Ron Weitzman, M.D. |
President and CEO | SVP, General Counsel | Chief Scientific Officer | Chief Business Officer | Chief Medical Officer (part-time) |
Large Commercial Opportunity still exists in Immuno-Oncology (IO)
Newly Diagnosed Patients Annually in 20262
Head and Neck Cancer (H+N)
1. Market opportunity estimates for PD-1, PDL-1 & anti-CTLA-4 Inhibitors - TD Cowen's Guide to Immuno-oncology
2. GlobalData; Incident cases diagnosed in 8MM 2026 (US, UK, Japan, China, France, Germany, Italy, Spain)
VISTA's Potential Commercial Impact
❖ The checkpoint market is large and growing fast1
❖ Despite the widespread use of checkpoint inhibitors, only 20% of patients experience an objective response
❖ Indications such as CRC see little to no benefit from current treatment options
❖ VISTA is implicated in numerous solid tumor types with large patient populations
Lack of Tumor Targeting is a Major Obstacle in IO Innovation
Industry Problem
Sensei's Solution
Conventional antibodies target immune checkpoints that are highly expressed in normal tissues, resulting in:Conditionally active antibodies are selectively targeted to the tumor microenvironment, potentially providing:
• Dose-limiting toxicities due to on-target/off-tumor action
• Little or no toxicity due to selective on-target/on-tumor action
• Pharmacological sink effect requires higher & more frequent dosing
• Suboptimal activity due to poor PK & dose-limiting toxicities
• Lower & less frequent doses with tumor-specific binding
• Powerful activity selectively focused on the tumor microenvironment
2011
2014
One new IO checkpoint inhibitor approved after the CTLA-4 and PD-1/PD-L1 group
2022
The TMAb Platform: pH-sensitive Antibodies Selectively Bind to Targets in the Low-pH Tumor Microenvironment
• Exploits the tumor microenvironment using pH-selective properties
• Intended to alleviate undesirable PK/PD properties:
• Dose-limiting toxicities due to on-target/off-tumor binding
• Higher and more frequent dosing due to poor pharmacokinetics
• Bolsters specific activities
• Unlocks previously undruggable immune targets
Innovative Pipeline of IO Drugs with Broad Commercial Potential
*Sensei has entered into a clinical supply agreement with Regeneron supporting the planned evaluation of SNS-101 in combination with Regeneron's anti-PD-1 therapy Libtayo® (cemiplimab) in a Phase 1/2 clinical trial in solid tumors.
*Sensei has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. The goal of this collaborative effort is to further elucidate the role of VISTA in immune checkpoint resistance and expand the potential of SNS-101 as a combination therapy beyond anti-PD-1.
STNESX-1T01 (VISTA)
VISTA is a Potent T cell Checkpoint Extensively Expressed on Myeloid Cells
VISTA is a B7 family member that inhibits T cell activation1
Immunosuppressive function believed to be mediated by PSGL-1 receptorExtensive VISTA expression on off-tumor myeloid-lineage cells demands a conditionally active antibody approach
Upregulated on immune suppressive myeloid-derived suppressor cells (MDSCs) via hypoxia2
Increased expression on tissue infiltrating immune cells upon checkpoint therapy failure3
IS ACTIVATED IN A pH SENSITIVE MANNER
Myeloid lineage cell or tumor cell (less common)
T-cell proliferation & activation
1 Wang et al, JEM, 2011
2 Deng et al, Cancer Immunonol Res 2019
3 Gao et al., Nat Med. 2017
4 Johnston et al., Nature 2019
VISTA has inherent pH sensitivity: its extracellular domain is uniquely rich in histidines4
10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sensei Biotherapeutics Inc. published this content on 02 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 April 2024 12:13:03 UTC.